Gilead Sciences Inc
NASDAQ:GILD

  • LAST PRICE
    79.2200
  • TODAY'S CHANGE (%)
    0.2000 (0.2531%)
  • Bid / Lots
    79.2100/ 1
  • Ask / Lots
    79.2200/ 4
  • Open / Previous Close
    79.2500 / 79.0200
  • Day Range
    79.0350
    80.1800
  • 52 Week Range
    72.8659
    89.7400
  • Volume
    2,342,226

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Pharmaceuticals - Diversified Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
GILD
Gilead Sciences Inc
98.5B
17.0x
-13.86%
AMGN
Amgen Inc
145.0B
19.2x
+1.96%
BMY
Bristol-Myers Squibb Co
102.2B
12.6x
+4.53%
GSK
GSK plc
74.8B
9.7x
+9.56%
HLN
HALEON PLC
37.7B
24.2x
---
VTRS
Viatris Inc
11.5B
6.4x
+2.13%
As of 2023-12-06

Company Information

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company's other products include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases.

Contact Information

Headquarters
333 LAKESIDE DRFOSTER CITY, CA, United States 94404
Phone
650-574-3000
Fax
650-578-9264

Executives

Chairman of the Board, Chief Executive Officer
Daniel O'Day
Chief Financial Officer
Andrew Dickinson
Executive Vice President - Corporate Affairs, General Counsel, Corporate Secretary
Deborah Telman
Executive Vice President - Pharmaceutical Development and Manufacturing
Stacey Ma
Executive Vice President - Research
Flavius Martin

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$98.5B
Revenue (TTM)
$27.4B
Shares Outstanding
1.2B
Dividend Yield
3.79%
Annual Dividend Rate
3.0000 USD
Ex-Dividend Date
12-14-23
Pay Date
12-28-23
Beta
0.24
EPS
$4.66
Book Value
$17.03
P/E Ratio
17.0x
Price/Sales (TTM)
3.6
Price/Cash Flow (TTM)
11.7x
Operating Margin
30.16%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.